News
UCLA to Commercialize Saliva-Based Tests for Cancer, Other Diseases With Help From S. Korean Partner
UCLA's Electric Field-Induced Release and Measurement (EFIRM) system could offer the early detection of cancers and other ...
Financial and other terms of the deal were not disclosed.
The program offers lower-cost, refurbished testing instruments as well as customer education, inventory management, and enhanced service agreements.
TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage ...
The all-virtual program is currently looking for a second cohort of novel diagnostics technologies, with a Sept. 30 deadline for new applications.
NEW YORK — The Scottish government has earmarked £800,000 ($1.1 million) to support the introduction of a Genedrive test to help prevent antibiotic-induced deafness in newborns within the country, ...
According to a company executive, the transactions will provide QuidelOrtho with greater financial flexibility while funding its continued growth.
WASHINGTON – In a presentation this week at the Next Generation Dx conference here, the National Cancer Institute's Wendy Rubinstein gave an update on the NCI's Vanguard study of multi-cancer early ...
The organization noted that US senators have introduced a bill to accelerate Medicare coverage for breakthrough devices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results